The landscape of clinical mycology is constantly changing. New therapies for malignant and
autoimmune diseases have led to new risk factors for unusual mycoses. Invasive …

Multiple sclerosis therapies include interferons, glatiramer, and multiple immunosuppressive
drugs. Discerning infectious risks of immunosuppressive drugs requires understanding their …

Abstract Sphingosine‐1‐phosphate (S1P) is a signalling lipid that regulates many cellular
processes in mammals. One well‐studied role of S1P signalling is to modulate T‐cell …

Introduction There continues to be an exponential rise in the number of small molecule
drugs that contain either a fluorine atom or a fluorinated fragment. While the unique …

Aging is characterized, amongst other features, by a complex process of cellular
senescence involving both innate and adaptive immunity, called immunosenescence and …

Human fungal infections are a historically neglected area of disease research, yet they
cause more than 1.5 million deaths every year. Our understanding of the pathophysiology of …

Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …

Abstract Purpose of Review This paper will systemically review the risk of infections
associated with current disease-modifying treatments and will discuss pre-treatment testing …

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …

The risk of infection associated with immunomodulatory or immunosuppressive disease-
modifying drugs (DMDs) in patients with multiple sclerosis (MS) has been increasingly …